Current treatment strategies in chronic myeloid leukemia

Current Opinion in Hematology

Volumn 19, Issue 2, 2012, Pages 102-109

  Guilhot, François ^a   Roy, Lydia ^a   Tomowiak, Cécile ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

interferon; scoring system; tyrosine kinase inhibitors

Indexed keywords

DASATINIB; IMATINIB; INTERFERON; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CHRONIC MYELOID LEUKEMIA; COMBINATION CHEMOTHERAPY; CYTOGENETICS; DRUG DOSE COMPARISON; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYTOGENETICS; DRUG THERAPY, COMBINATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84857063695     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32834ff610     Document Type: Review

References (31)

1. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112:4808-4817.
2. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408-2417. (Pubitemid 44903745)
3. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009; 27:6041-6051.
4. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome positive chronic myeloid leukemia after failure of interferon-Alpha. Blood 2003; 102:83-86. (Pubitemid 36759639)
5. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103:2873-2878. (Pubitemid 38451654)
6. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28:424-430. The study concluded that continued follow-up is needed to determine the clinical significance of earlier responses on high-dose imatinib.
7. Baccarani M, Druker B, Cortes J, et al. 24 months update of the TOPS study: A phase III, randomized open-label study of 400 mg/d (SD-IM) versus 800 mg/d (HD-IM) of imatinib mesylate in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase. Blood 2010; 114:abstract 337.
8. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-Adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-A in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29:1634-1642. The study found that achievement of MMR by month 12 is directly associated with improved survival.
9. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363:2511-2521. The study concluded that the addition of Peg-IFNa2a to imatinib therapy resulted in higher rates of molecular response in patients with CP-CML.
10. Gafter-Gvili A, Leader A, Gurion R, et al. High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients: Systematic review and meta-Analysis. Am J Hematol 2011; 86:657-662.
11. Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: A European LeukemiaNet Study. Blood 2009; 113:4497-4504.
12. Guilhot F, Guilhot J. Predicting response in CML. Blood 2011; 117:1773-1774.
13. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood 2011; 118:686-692.
14. Marin D, Ibrahim AR, Goldman JM. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol, 2011; 29:3944-3945.
15. Jabbour E, Kantarjian H, O'Brien S, et al. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood 2011; 117:1822-1827.
16. Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010; 95:224-231.
17. Mcweeney SK, Pemberton LC, Loriaux MM, et al. A gene expression signature of CD34 cells to predict major cytogenetic response in chronic phase chronic myeloid leukemia patients treated with imatinib. Blood 2010; 115:315-325.
18. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010; 116:3758-3765.
19. Jabbour E, Kantarjian H, O'Brien S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011; 118:4541-4546. The study analyzed the association between achievement of early complete cytogenetic response and EFS in patients with newly diagnosed CML.
20. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2011. doi:10.1200/JCO.2011.38.6565. [Epub ahead of print]
21. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251-2259. The study evaluated the efficacy and safety of nilotinib in patients with newly diagnosed Philadelphia chromosome-positive CML in the chronic phase.
22. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260-2270. The study concluded that dasatinib, compared with imatinib, induced significantly higher and faster rates of complete cytogenetic response and MMR.
23. Jorge E, Cortes JE, Maru A, Carmino De Souza CA, et al. Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia: BELA trial: 24-month follow-up. Blood 2011; suupl. 1:abstract 455.
24. Kantarjian H, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12:841-851.
25. Kantarjian H, Shah NP, Cortes JE. Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION. J Clin Oncol 2011; 29 (Suppl):abstract 6510.
26. Guilhot F, Roy L, Saulnier PJ, Guilhot J. Interferon in chronic myeloid leukaemia: Past and future. Best Pract Res Clin Haematol 2009; 22:315-329.
27. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11:1029-1035. The study assessed whether imatinib can be discontinued without the occurrence of molecular relapse in patients in complete molecular remission.
28. Bhattacharya S, Zheng H, Tzimas C, et al. Bcr-Abl signals to desensitize chronic myeloid leukemia cells to IFNa via accelerating the degradation of its receptor. Blood 2011; 118:4179-4187.
29. Simonsson B, Gedde-Dahl T, Markevarn B, et al. Combination of pegylated interferon-Alpha2b with imatinib increases molecular response rates in patients with low or intermediate risk chronic myeloid leukemia. Blood 2011; 118:3228-3235. The study found that lower doses of Peg-IFNa2b may enhance tolerability and could be considered in future protocols.
30. Cortes J, Hochhaus A, Hughes T, et al. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 2011; 29:524-533.
31. Jabbour E, Kantarjian H, O'Brien S, et al. Front-line therapy with secondgeneration tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: What is the optimal response? J Clin Oncol 2011; 29:4260-4265.